Hematology-American Society of Hematology Education Program

Article	Citations
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	100
The varieties of therapeutic experience: navigating treatment options for patients with PNH	94
Mastocytosis demystified	67
On the horizon: upcoming new agents for the management of ITP	64
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	54
Bispecific antibody therapies	45
Labor and delivery: DIC, HELLP, preeclampsia	45
Challenges and opportunities in the long-term management of immune-mediated TTP	44
Inpatient recognition and management of HLH	36
Recognizing, defining, and managing CAR-T hematologic toxicities	34
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment	32
Anticoagulation at the end of life: whether, when, and how to treat	31
Your chemo is no good here: management of high-risk MCL	30
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	29
Neurological manifestations of MGUS	29
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	28
Has PD-1 blockade changed the standard of care for cHL?	28
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	28
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	27
New therapies in hemophilia: extend the half-life, mimic, or rebalance?	27
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	27
Where do immunotherapies stand in management of acute leukemia in adults?	27
Troubleshooting heparin resistance	26
Optimizing outcomes in secondary AML	26
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	25

Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	25
How to assess hemostasis in patients with severe liver disease	24
Donor selection, graft engineering, and dosing oh my!	24
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	24
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL	24
New approaches to tackle cytopenic myelofibrosis	24
Fitness and frailty in myeloma	24
BV and beyond: how to incorporate novel agents into PTCL management	23
Divergent paths: management of early relapsed follicular lymphoma	23
Selecting initial therapy in CLL	23
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	22
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	22
MGCS: where do we stand today?	22
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	21
Consumptive coagulopathy in the ICU	20
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	20
What's new in hereditary hemorrhagic telangiectasia?	20
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?	20
Management of TKI-resistant chronic phase CML	19
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	19
Demystifying autoimmune HIT: what it is, when to test, and how to treat	19
Hematology 2022—what is complete HLA match in 2022?	19
Management of limited-stage Hodgkin lymphoma	19
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?	19
How to manage hemostasis in patients with liver disease during interventions	19
How to diagnose and manage antiphospholipid syndrome	19
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	19
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	18
Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 202	18
Management of marginal zone lymphomas	18
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL	17
Thrombosis questions from the inpatient wards	17
Transplant in AML with measurable residual disease: proceed or defer?	17
Special considerations in GI bleeding in VWD patients	17
Atypical CML: diagnosis and treatment	17
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	17
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma	17
CNS prophylaxis in aggressive B-cell lymphoma	17
Approaches to management of HIT in complex scenarios, including cardiac surgery	16
Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing	16
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	16
Organ function indications and potential improvements following curative therapy for sickle cell disease	16
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	16
Management of autoimmune hemolytic anemia	16
Alloimmunization and hyperhemolysis in sickle cell disease	16
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma	15
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	15
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	15
Pregnancy management for patients with bleeding disorders	15
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	14

Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes	14
What makes a pediatric or young adult patient an appropriate transplant candidate?	14
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	14
Cytoreduction for ET and PV: who, what, when, and how?	14
Pegylated interferon: the who, why, and how	14
Ph− ALL: immunotherapy in upfront treatment	14
Treatment of VTE in the thrombocytopenic cancer patient	14
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	14
POEMS syndrome: diagnosis, treatments, and outcomes	14
Thrombocytopenia in pregnancy	14
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	13
Should we use bisphosphonates to treat bone complications in sickle cell disease?	13
Future directions in transplantation for aplastic anemia	13
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?	13
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	13
Next-generation therapy for lower-risk MDS	13
What is the ideal approach—doublet, triplet, or quadruplet(s)?	13
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS	13
Clinical manifestations of telomere biology disorders in adults	13
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	13
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS	13
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era	13
Monoclonal gammopathy of renal significance from a hematologic perspective	13
Novel therapies upon failure of HMA plus venetoclax	12
Approach to the patient with suspected hypereosinophilic syndrome	12
What to know about rare B-cell malignancies in 2025	12
Sequencing bispecific antibodies and CAR T cells for FL	12
The role of stem cell transplant (auto and allo) in PTCL and CTCL	12
Warm autoimmune hemolytic anemia and the best treatment strategies	12
Managing side effects: guidance for use of immunotherapies in multiple myeloma	12
Managing patients with a history of arterial disease and new venous thromboembolism	12
The aging hemophilia patient	12
When it's not Glanzmann thrombasthenia or Bernard-Soulier syndrome: diagnosing other qualitative platelet disorders	11
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	11
Barriers to accessing cellular therapy for patients receiving care in community practices	11
In 2022, which is preferred: haploidentical or cord transplant?	11
Porphyria cutanea tarda: a unique iron-related disorder	11
Molecular surprises in evaluations of red cell disorders	11
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	11
Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD	11
What is the best induction for myeloma for the fit patient?	11
The approach of HMA plus VEN with or without BMT for all patients with AML	11
IV iron formulations and use in adults	11
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	11
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice	10
When should we use it? The role of brentuximab vedotin in 2024	10
von Willebrand disease and heavy menstrual bleeding: when and how to test	10
Sequencing therapy in relapsed DLBCL	10
Long-term prophylaxis: what are our options and how to define success?	10
Proactive management to improve outcomes of high-risk pregnancy in people with sickle cell disease	10
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders	10
Clonal hematopoiesis in frequent whole blood donors	10
Updates in antithrombotic therapy in coronary and peripheral artery disease	10
Implementation failure: thromboprophylaxis in ambulatory patients with cancer	9
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?	9
Management of Fanconi anemia beyond childhood	9
Updates in the management of newly diagnosed chronic lymphocytic leukemia	9
Diagnosis and management of cold agglutinin disease	9
Are transplant indications changing for myelofibrosis?	9
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	9
New definitions for antiphospholipid syndrome: ready for clinical use?	9
Novel platelet products including cold-stored platelets	9
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?	9
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia	9
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	9
Diagnosis of bleeding disorder of unknown cause: how many tests are enough to diagnose BDUC?	9
Risk-stratification in frontline CLL therapy: standard of care	9
From treatment to biology and back: managing iron overload in transfused hemoglobinopathies	9
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	8
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	8
Renal manifestations of MGUS	8
The first relapse in multiple myeloma: how to pick the next best thing	8
(Un) Diagnosing von Willebrand disease	8
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	8
New investigational combinations for higher-risk MDS	8
Newborn screening initiatives for sickle cell disease in Africa	8
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	8
Multiple myeloma: a paradigm for blending community and academic care	8
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	8
Using disease-modifying therapies in sickle cell disease	8

Clonal evolution in inherited marrow failure syndromes predicts disease progression	8
The intersection of sickle cell disease, stigma, and pain in Africa	8
When to consider inherited marrow failure syndromes in adults	8
Amyloid consults do not have to be vexing	8
Transplantation in CML in the TKI era: who, when, and how?	7
Maintenance strategies for relapse prevention and treatment	7
Novel clinical care models for patients with sickle cell disease	7
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	7
Potential and emerging therapeutics for HHT	7
Challenges to successful outcomes in AYAs with ALL and potential solutions	7
Acute lymphoblastic leukemia in young adults: which up-front treatment?	7
New age HCT conditioning regimens: what works and why?	7
Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?	7
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	7
Sickle cell disease in India: the journey and hope for the future	7
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program . 2023;2023(1):573-580.	7
Mitigating and managing infection risk in adults treated with CAR T-cell therapy	7
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease	7
Ph+ ALL in 2022: is there an optimal approach?	7
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma	7
Current use of bispecific antibodies to treat multiple myeloma	7
How to manage ITP with life-threatening bleeding	6
Cellular therapy for multiple myeloma: what's now and what's next	6
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	6
Optimizing the “right” patient selection for treatment for sickle cell disease	6
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	6
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program . 2021;2021:621-627.	6
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line	6
Epidemiology and treatment of priapism in sickle cell disease	6
Dual-targeted regimens for the frontline treatment of CLL	6
Optimal approach to T-cell ALL	6
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care	6
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program . 2023;2023(1	6
Ph+ ALL: new approaches for upfront therapy	6
The role of MRD monitoring and options for CLL management in relapsed/refractory disease	6
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	6
Late complications and long-term care of adult CAR T-cell patients	6
Incorporating gonadal health counseling into pediatric care of sickle cell patients	5
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	5
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	5
Deconstructing gene therapy in hemophilia for the clinician	5
Novel approaches to acute graft-versus-host disease prevention	5
High-grade B-cell lymphomas: high difficulties to diagnose and treat?	5
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	5
Inflamed—HLH, MAS, or something else?	5
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT	5
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	5
Buckle up! Managing surgery in patients with bleeding disorder of unknown cause	5
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	5
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	5
Mutational screening to improve the transplantation decision-making process in MDS	5
Givosiran: a targeted treatment for acute intermittent porphyria	5
Platelet components and bacterial contamination: hospital perspective 2022	5
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	5
Endless possibilities and how to exploit them? What is the optimal treatment sequence?	5
Identifying and treating iron deficiency anemia in pregnancy	5
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas	5